Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | -143.04% | -90.44% | 7.94% | 104.57% | -89.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -143.04% | -90.44% | 7.94% | 104.57% | -89.56% |
| Cost of Revenue | -164.00% | 5.23% | -49.73% | 443.08% | -91.21% |
| Gross Profit | -119.78% | -177.78% | 122.83% | -95.51% | -86.74% |
| SG&A Expenses | -87.05% | -62.82% | -46.94% | -13.78% | 2.31% |
| Depreciation & Amortization | -20.98% | 33.54% | -38.19% | -17.60% | -29.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -82.04% | -45.52% | -45.47% | 179.85% | -16.74% |
| Operating Income | 78.36% | 36.39% | 47.29% | -24.08% | -43.78% |
| Income Before Tax | 7.05% | 21.46% | 25.14% | 38.88% | 30.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.05% | 21.46% | 25.14% | 38.88% | 30.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.05% | 21.46% | 25.14% | 38.88% | 30.61% |
| EBIT | 78.36% | 36.39% | 47.29% | -24.08% | -43.78% |
| EBITDA | 87.39% | 48.01% | 49.81% | -32.98% | -71.67% |
| EPS Basic | 9.20% | 24.52% | 28.46% | 43.87% | 35.07% |
| Normalized Basic EPS | 81.63% | 24.54% | 29.27% | 56.44% | 40.96% |
| EPS Diluted | 9.20% | 24.52% | 28.46% | 43.87% | 35.07% |
| Normalized Diluted EPS | 81.63% | 24.54% | 29.27% | 56.44% | 40.96% |
| Average Basic Shares Outstanding | 3.11% | 4.25% | 4.73% | 9.04% | 6.24% |
| Average Diluted Shares Outstanding | 3.11% | 4.25% | 4.73% | 9.04% | 6.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |